Parkinson’s Disease Rat Model

Anti-Tumor Drug Efficacy Evaluation
Humanized Immune Checkpoint Mouse Models and Efficacy Services
Autoimmune Disease Efficacy Evaluation
Autoimmune Nephropathy Models and Efficacy ServicesAsthma Models and Efficacy ServicesSystemic Lupus Erythematosus (SLE) Models and Efficacy ServicesSjögren's Syndrome Models and Efficacy ServicesNeuroimmune Diseases Models and Efficacy ServicesAutoimmune Dermatoses Models and Efficacy ServicesInflammatory Bowel Disease (IBD) Models and Efficacy ServicesRheumatoid Arthritis (RA) Models and Efficacy ServicesImmune Reconstitution Autoimmune Disease Models and Efficacy Services
Metabolic Disease Efficacy Evaluation
Obesity Models and Efficacy ServicesType II Diabetes Models and Efficacy ServiceType I Diabetes Models and Efficacy ServicesAndrogenetic Alopecia (AGA) Models and Efficacy ServicesMASH Models and Efficacy ServicesChronic Liver Fibrosis Models and Efficacy ServicesAcute Liver Injury Models and Efficacy ServicesCholestasis Models and Efficacy ServicesAlcohol-related Liver Disease (ALD) Models and Efficacy ServicesChronic Kindey Disease (CKD) Models and Efficacy ServicesActue Kindey Disease (AKD) Models and Efficacy ServicesDiabetes Nephropathy (Diabetic Kidney Disease) Models and Efficacy ServicesSarcopenia Models and Efficacy ServicesGout/Hyperuricemia Models and Efficacy ServicesFemale Reproduction Models and Efficacy Services
Neurological Disease Efficacy Evaluation
In Vitro TestingBehavioral AnalysisIn Vivo Drug Efficacy EvaluationIn Vivo Biochemical ExaminingParkinson’s Disease Rat Model
Cardiovascular Diseases Efficacy Evaluation
Heart Failure Models and Efficacy ServicesHypertension Models and Efficacy ServicesAtherosclerosis Models and Efficacy ServicesAdvanced Cardiovascular and Metabolic Complication Models and Efficacy ServicesHyperlipidemia Models and Efficacy ServicesHypertropic Cardiomyopathy Models and Efficacy ServicesStroke Models and Efficacy ServicesThrombosis Models and Efficacy Services
Bioanalytical Services
Phenotyping Services
Oncology PlatformMetabolism PlatformEfficacy and Pathology Platform
Non-GLP Toxicity Assessment Services
Cell Therapy & Gene Therapy Efficacy Evaluation
Disease Rat Models
60% HFD Induced DIO Rat ModelsAdenine-induced Rat CKD Model5/6 Nephrectomy-induced Rat CKD ModelCCL4-induced Chronic Liver Fibrosis Models in SD RatCDAHFD-induced Rat MASH Model45％HFHS+STZ induced Type I Diabetes Models in SD RatOVX-induced Rat Osteoporosis ModelMCAO-induced CIS Model in SD Rat2K1C-induced Hypertension Model in SD Rat
Infectious Disease Efficacy Evaluation
About Our Biosafety LaboratoryIn vitro Drug Efficacy EvaluationIn vivo Drug Dfficacy Evaluation

Parkinson's disease (PD) is a progressive neurodegenerative disease that is characterized by a combination of motor and non-motor symptoms. GemPharmatech has successfully developed a PD rat model by precisely stereotaxically injecting 6-OHDA into both the Substantia Nigra pars compacta (SNc) and Ventral Tegmental Area (VTA). This well-constructed PD model offers a powerful tool for in-depth research and drug development, enabling a more comprehensive understanding and potential therapeutic interventions for PD.


6-OHDA induced PD rat model



▎Model Construction Strategy


1.png

Data collection

  • Body weight

  • Survival proportion

  • Behavior test

  • Hematoxylin-eosin staining

  • Nissl body staining

  • Immunofluorescence staining (TH, Iba1, GFAP)

 

▎Body Weight Change and Survival Rate of the PD Model


2.png

(data presented as Mean±SEM，n=6)


The body weight of the PD model was lower than the control group after unilateral stereotaxic injection. In the first week after unilateral stereotaxic injection of 6-OHDA, approximately 15% death was observed.

 

▎Confirmation of Successful Induction of PD by 6-OHDA

 

3.png

(data presented as Mean±SEM，n=6)


Three weeks after unilateral stereotaxic injection of 6-OHDA, subcutaneous injection of apomorphine (0.5 mg/kg) caused the rats to rotate toward the uninjured side. Rats that rotated more than 210 times (7 turns/minute) within 30 minutes were identified as PD models.

 

▎Behavior Test: Rotarod


8.png 


The PD rat model showed deficits in motor learning and motor coordination in the rotarod test.

 

▎Pathology: HE and NISSL body staining of Substantia Nigra


4.png


Unilateral stereotaxic injection of 6-OHDA into both the Substantia Nigra pars compacta (SNc) and Ventral Tegmental Area (VTA)

 

▎Pathology: IBA1+ and GFAP+ staining in Substantia Nigra


5.png


Eight weeks after 6-OHDA injection, IBA1+ (microglial marker) and GFAP+ (astrocyte marker) staining was significantly increased in the injection position of the substantia nigra of the PD model.

 

▎Pathology: TH+ neurons in Substantia Nigra and Striatum


图片3.jpg


Eight weeks after 6-OHDA injection, TH+ neuron loss was observed in the striatum and substantia nigra on the injured side of the PD model.

 

▎Pathology: IBA1+ and GFAP+ staining in Striatum


6.png


Eight weeks after 6-OHDA injection, IBA1+ and GFAP+ staining in the striatum showed no difference among three groups.

 

▎Pathology: IBA1+ and GFAP+ staining in Hippocampus


7.png


Eight weeks after 6-OHDA injection, IBA1+ and GFAP+ staining in the hippocampus showed no difference among three groups.


Data request in progress, please wait…